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STEM CELL TRANSPLANTATION (SCT) FOR PATIENTS WITH FAN- 
CONI'S ANEMIA (FA) WITH LOW DOSE CYCLOPHOSPHAMIDE (CY) 
AND ANTITHYMOCYTE GLOBULINS (ATG) WITHOUT THE USE OF 
RADIATION THERAPY, A PROSPECTIVE STUDY 
Ayas, M.F.; Al-J~fii, A.H.; ALMahr, M.; I~lrao~d, M.; Mltstafa, 
M.M.; Mol*,rsa, E.; Shalaby, L.; El-Solb, H. KiJ~g Faisal Specialist Hos- 
pital & Resea~vh Ce,lte'r. Depart77zeJ~t of Pediatric He~tzatology-O*~colo- 
gy, Riyadh, Smldi Arabia. 
Background: Radiation therapy is a risk factor for development 
of secondary malignancy in patients (pts) undergoing SCT for 
aplastic anemia. This risk is higher in FA pts because of their 
defective DNA repair mechanisms. In May 1999, we began a 
prospective study with low dose CY and ATG for conditioning 
FA pts without radiation and report here our results. Patients and 
Methods: From May 1999 through August 2002, 15 pts with FA 
underwent allogeneic SCT at KFSH&RC. Median age was 8.3 
years (range, 5.2-15 years). Diagnosis was confirmed by chromo- 
somal breakage studies with Mitomycin-c and Diepoxybutane 
(DEB). All pts had bone marrow examination before SCT and 
none had evidence of leukemia, myelodysplasia, or any clonal 
abnormalities. All pts had fewer than 12 blood product ransfu- 
sions in the year before BMT. Fourteen donors were HLA-iden- 
tical siblings, and one was an HLA identical father. All donors 
had negative chromosomal breakage studies. Harvested marrows 
were not manipulated, and the median CD 34 dose was 6.6 x 10 ° 
(range, 2.1-24 x 10 <' ) per kg of recipient body weight. The condi 
tioning was with CY 15 mg/kg/day i.v. for 4 days, and ATG 40 
lng/kg i.v. for 4 days. Graft vs. Host disease (GVItD) prophyla~s 
was with Cyclosporin and ATG (20 mg/kg for 6 doses post SCT). 
Donor engraftment was evaluated on day +28 by showing trilin- 
eage engraftment in the bone marrow and by VNTR analysis (for 
same sex SCT) or FISH (for opposite sex SCT) on peripheral 
lymphocytes. Results: All pts engrafted and are now alive and 
transfusion independent with a median follow up time of 15.5 
months (range, 1.2- 41.5 months). Median time to engraftment 
(ANC of > 0.SX10';/L) was 12 days (range, 9-28 days), median 
time to self sustaining platelet count of > 20X10VL was 30 days 
(range, i6-139 days). Three pts developed acute skin GVtID 
(grade 2) and one developed sldn and gut aGVHD(grade 2), all 
pts responded steroids. Thus far, no patients developed chronic 
GVHD. Mncositis grade > 2 developed in all pts. Four patients 
developed hemorrhagic cystitis. Conclusions: Use of radiation can 
be avoided in the conditioning of pts with FA undergoing Allo- 
geneic SCT. Low dose cyclophosphamide at 60 mg/kg with ATG 
can result in good engraftment with reas'onably tolerated to,city. 
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PROSPECTIVE MRD MONITORING BY RQ-PCR; CLINICAL FEASIBILITY 
IN EARLY DETECTION AND MANAGEMENT OF CML RELAPSE AFTER 
ALLOGENEIC SCT 
Kiln, D.; Kiln, Y.; Lee, S.; Kiln, t~; H~,a~g, .7.; Khan, C. Catholic 
He~atopoietic Ste~ Cell Trcm,s~h~tatio~z Ce*~ter, The Catholic UMver- 
sity of Korea, Sem,l, So~ttl, Korea. 
Background and Objectives. Immunotherapy at early phase 
relapse after stem cell transplantation (SCT) for chronic mye]ogc- 
nous leukemia (CML) induces ahigher ate of complete remission 
and lower side effects. Real-time quantitative RT-PCR (RQ- 
PCR) has been l~lown to be useful for early detection of CML 
recurrence. However, there has been no consensus about at which 
level RQ-PCR at early period after SCT immunotherapy should 
be given to prevent disease progression. Design and Methods. 
Using RQ-PCR, RT-PCR, and fluorescence in situ hybridization 
(FISH), we prospectively monitored minimal residual disease 
(MRD) in consecutive 45 patients who underwent SCT for CML. 
Patients with quantitative molecular elapse (QMR, rising BCR- 
ABL/ABL>0.01) were randomly assigned to either ,z0 therapy 
(group A) or i~ltTHzHlotherapy (group B) arm. Disease progression to 
molecular cytogenetic relapse (MCR, FISH>5.24%) was com- 
pared between two groups, hnnrunotherapy of immunosuppres- 
sants withdrawal, DLI (CD3+, 1.0 X 10e'/kg), and/or interferon 
was given to patients in group A when disease progressed to 
MCR, as it was given at he time of diagnosis to those in group B 
or initially relapsed MCR Results. 13 patients were diagnosed as 
QMR at a median of 3 months (2.8-6.3 months) post-HSCT. 
MCR occurred in all 6 in group A and 2 of 7 in group B following 
QMR, meanwhile 4 were diagnosed as initial MCR. The probabil- 
ity of MCR was significantly different between two groups (group 
A 100% vs group B 35.7%, P=0.002). Molecular emission (MR) 
was achieved in 11 (64.8%) of 17 patients at a median of 3.3 
months (i.2-11.4 months) after immunotherapy. The probability 
of disease free survival in 11 patients in MR was 87.5%; 10 of 11 
patients remain alive in MR more than 7.5 23.2 months. Acute 
and chronic GVHD developed in 29.4 % and 76.5%, respectively, 
and marrow suppression, on the contrary, did not develop. Treat- 
ment related to,cities developed in 2 patients (11.8%) Interpreta- 
tion and Conclusions. The fact that normalized BCR-ABL trau- 
script rising higher than 0.01 within 6 months after SCT heralded 
disease progression and substantial of the relapsed achieved 
molecular emission after early imlnunotherapy with reduced 
intensity revealed that RQ-PCR is a powerful tool in MRD moni- 
toring and managing CML relapse after SCT. 
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COMPARATIVE OUTCOME OF UNRELATED HEMATOPOIETIC STEM 
CELL TRANSPLANTATION (HSCT) WITH CORD BLOOD (CB) VS BONE 
MARROW (BM) IN PEDIATRIC RECIPIENTS 
Dr//e, j1;  D~wd, 3i.l; 3doghrabi, A.I; Roztsseau, p.2; ~'Vagller, E.l; 
f~tc'lao,~, M.1; Barrette, S. i, Ber'm'teiTz, M.1; Cha'mpa~lze, ,7.i David, 
M.1; De~;lers, ft. ;; ChaT;;pag;;e, AI.A. ; 1. Sai;;te av;;.rti;;e Hospital, ;!/Io;;- 
treal, QC, Ca~ada; 2. Notre Da'nm Hospital, MoTltreal, QC, Cmlada. 
From 06.1996 to 07.2002, 62 unrelated HSCT were undertaken 
in 57 children (36M/22F; median age 7.0 years.) at our institution. 
Stem cell source was CB in 33 and BM in 29. Forty-three patients 
had hematological 1-nalig~lancies and 14 inherited syndromes. HLA- 
A and -B typing was performed by serology for CB and molecularly 
for BM, whereas molecular typing' was used for HLA-DRbl for 
both. Donor-recipient HLA mismatches (MM) were only observed 
in CB-patients: 0 MM=I; 1MM =16; 2MM=16. Time from search 
initiation to HSCT was not differeut in the 2 cohorts, but time from 
decision to HSCT was 36 days shorter in CB recipients (p<0.0001). 
Conditioning regimens included cyclophosphamide with TBI or 
Busulfan _+ VP 16. ATG was administered for 57 transplants. GVt ID 
prophylaxis included cyclosporin + methotrexate for BM-patients, 
and cyclosporin +- steroids _+ methon'exate for CB-patients. Twenty 
CB patients received G-CSF. Supportive care guidelines were iden 
tical in the two groups. Primary graft failure occurred iu 6 CB and 3 
BM HSCT. Acute grade II to IV GVHI) occurred in 5 CB and 1 
BM recipients. Limited cGVHD occurred in 3 CB and 1 BM recipi- 
ents and no patients howed extensive cGVttD. Death occurred in 
12 CB-patients and 11BM patients (multiple organ failure=4 and 5, 
infection=4 and 1, relapse=t~ and 3, and other=l and ~,' respectively)., 
:l'hirty-four children are currently alive, 30 in CR, 3 in relapse and 1 
with autologous reconstitution (IIunter disease). Median time for 
engTaftement, Kaplan-Meicr TRM, OS and EFS are summarized in
table. We conclude that partially HLA-mismatched CB-HSCT is a 
suitable alternative to frilly HLA-lnatched BM-HSCT with no 
increased TRM and comparable outcomes. Consideration should be 
given for earlier selection of CB units for potential recipients. Table 
I summarizes the major clinical end-points: 
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I Median time [ Median time [ 
Median I IolANC~05 I folplatelet, j IRMat Ogat36 {EFSat36nlomhs 
nucleamdce/I I x 109/t ] e50x 10.921 day+100 illolllbs { forllcmatological 
doseintused [ ~range),in (range) ,in [ ma/ignancie~ 
days [ d~t) s
i 
CB 3.7x10.7/kg : 28t22-491 ] 42(18-591 258±7.8% 62±9.3% ] 39. +-12,2% 
i 
( 2-381 ! J 
5 I×lf) 8/kg I t I 
BM (1688~ 22¢14357 1275(20-129) 114±62% 60.1±9.9% 51.8.+.129% 
I 
ANC: Absolute Neutl oplnl Count; TRM: "l'reatnlcnl Related MOltalitv: OS: Ovel all Sulvival: EFS: 
Event Flee Sulwival, e~ent defined by d ath or relapse: NA: no available; NS: no significant 
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UNIVERSAL OUTPATIENT IMMUNOTHERAPEUTIC APPROACH FOR 
HEME MALIGNANCIES IN THE ABSENCE OF DONOR CHIMERISM: 
ANTI-TUMOR RESPONSES IN HLA-HAPLOIDENTICAL CELL INFUSIONS 
IN IOOCGY TREATED HOSTS 
Co/via, G.Ad; Lambert, id; Lmn, L.Gd, Rathore, Rd; Falvev, M.Td; 
Abedi, Md; Quesenberry, p.jd; Elfenbein, G.J. ~ 1. Adele R Decof 
Cancer Center, Roger Williams Medical Center, Providence, RI; 
2. DivisioTz of Hematology, University Hospital of GeTzeva, Geneva, 
Switzerland. 
Previously, we studied cellular immunotherapy with HLA-identi- 
cal sibling donors using 100cGy conditioning and infusing lxl08 
CD3+ cells/kg from non-mobilized peripheral blood. An impres- 
sive complete response (CR) rate was achieved in 4 of 11 patients 
(pts) with refractory hematologic malignancies (Blood 100:442, 
2002). Responding pts were transiently or permanently chimeric. 
However, only approximately 35% of pts otherwise ligible for 
allogeneic BMT have an HLA-identical sibling donor. On the 
other hand, nearly 100% of pts have HLA-haploidentical (HLA- 
H) donors, making HLA-H BMT an attractive area of investiga- 
tion. We performed 15 HLA-H peripheral blood stem cell (PBSC) 
infusions in pts with refractory heme malignancies. The CD3+ 
dose was 1-2x10 s cells/kg infused along with 2-4x106 CD34+ 
cells/kg. G-CSF (10 ug/kg for 3 days was used to mobilize PBSC. 
The transplant conditioning reghnen was 100cGy TBI on day 0. 
Median age was 55 (range 50-72). Diagnoses were: AML(4), 
CML(1), NHL(5), MDS(1) and MM(4). Donor chimerism was 
measured Q2 weeks. One treatment related death (7%) occurred 
from grade 1V AGVHD in apt  with 100% chimerism. Most pts 
had a transient febrile syndrome termed "haplo-immunostorm." 
Pts had mild pancytopenia starting 3 wks after HLA-H, most 
requiring brief transfusion support. Four nrajor clinical responses 
occurred. All of these responses were in the absence of measurable 
donor chimerism (<5%). All evaluable pts with AML and one with 
NHL achieved a CR. In summary: 1) very low dose TBI of 100cGy 
followed by HLA-H transplant is a biologically active treatment 
that eradicated far advanced isease; 2) all tumor responses 
occurred outside of detectable chimerism; 3) HLA-H with PBSCT 
is well tolerated with minimal non-hematologic to,city for the 
majority of pts; and 4) this is the first report of successful outpatient 
haploidentical inmmnotherapy achieving clinical responses for 
patients with end stage, refractory malignancies. Hypotheses con- 
cerning the mechanism ofthe biological effect include: 1) an initial 
graft vs. tumor cell kill after which donor cells are rejected, 2) an 
alteration of the host innnune response augmenting minor immu- 
nity or breaking host tumor tolerance, 3) persistent on-detectable 
micro-chimerism, or 4) a combination ofany of the three. 
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SUSTAINED ENGRAFTMENT OF HLA-MATCHED RELATED, T-CELL 
DEPLETED (TCD), PERIPHERAL BLOOD STEM CELL (PBSC)/BONE MAR- 
ROW (BM) TRANSPLANTS IN ADULTS WITH HEMATOLOGIC MALIG- 
NANCIES WITHOUT THE USE OF ANTITHYMOCYTE GLOBULIN (ATG) 
Jakz~bowski, A.A.; Castro-3/lalaspinal H.; Ke'rnmT, N.; Papadopoulos, 
E.; PeJ~ales, M.; Y0ztng, ft.; T,~omas, A.; O'Reil!y, R.J. Memorial Slom~ 
Ketterhzg CaTzcev Cen~e'~; New ~'rk, N}~ 
Acute and chronic GvHD, major causes of post-transplant mor- 
bidity and mortality, can be prevented by TCD. A limitation to 
the effectiveness of such transplants is the risk of graft 
rejection(GR)/failure(GF) caused by radioresistant, donor-reactive 
host T cells, which regenerate after transplant. Initial trials of 
TCD BM grafts from HLA matched siblings, showed a GF inci- 
dence of <14% in adults, vs.<5% for similarly matched unmodi- 
fied BM grafts. Previous work identified a conditioning regilnen 
of hyperfractionated total body irradiation (HTBI), thiotepa nd 
cyclophosphamide with ATG which reduced GF to <2%. Howev- 
er, studies of ATG recipients demonstrated delayed immune 
reconstitution, and a prolonged time 'at risk' for opportunistic 
infections.We hypothesized that high CD34+ cell doses coupled 
with HTBI,  thiotepa (51ng/kg)x2d and fludarabine 
(25mg/me2)x5d might obviate the need for ATG. Such a regimen 
has been evaluated in 22 adult transplants. PBSC and BM grafts 
were depleted o fT  cells by Isolex 300i CD34 selection + E-roset- 
ring, and SBA agglutination +E-rosetting, respectively . There 
were 13 males and 9 females, median age 46 yrs(range 19-60). 
Diseases: AML CRI(7), AML CR2(1), ALL CRI(1), biphenotypic 
acute leukemia CRI(2), CML(4), MDS-RAEBIT(2), NHL(5). 
Median follow-up: 201d(13-446). Two patients received BM and 
20 PBSC grafts. By d+30, 21 patients had an ANC)500 (1 patient 
too early (TE)), and 14 had platelets (plts) > 50k (1 TE). By 
d+100, 21 had an ANC >500 (1 TE), and 15 had >50k plts (1 TE, 
2 died early). Median time to ANC >500 for all patients was 
12d(range 10-21), and to plts >50k for 15 patients was 18d(range 
14-96). No patient developed acute (20 evaluable) or chronic (15 
evaluable) GvHD. Chimerism studies on BM at d+100 showed 
I2/I5 patients were 100%, 2/i5 were 95-98% donor (1/15 not 
evaluated). There have been no GR/GFs. Two patients with sec- 
ondary AML relapsed, one at 2 months responded to DLI, and is 
100% donor in remission at 6 months, and 1 at 10 months who 
died of complications. These results suggest that this regimen is 
sufficient o secure engraftment of HLA-matched TCD trans- 
plants without he addition of ATG. The influence of this regi- 
men on immune reconstitution is under study. 
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MALE PREDOMINANCE AMONG JAPANESE ADULT PATIENTS WITH 
LATE-ONSET HEMORRHAGIC CYSTITIS (HC) AFTER HEMATOPOIETIC 
STEM CELL TRANSPLANTATION (HSCT) 
Asano, Y.; Kanda, Y.; Ogawa, N.; Ogawa, S.; C,~iba, S.; Hh'ai, H. Depm-t- 
meat of Cell Therapy & Tram'plantation 34edicine, University of Tokyo. 
Background: Late-onset HC after HSCT is mainly caused by 
viral infections, and therefore, its incidence and risk factors may 
differ among populations. Patient and methods: We retrospective- 
ly analyzed the records of 141 Japanese adult patients who under- 
went first allogeneic HSCT from June 1995 to August 2002 at the 
University of "Tokyo Hospital. Prevention of cyclophosphamide- 
induced HC was performed with mesna and forced diuresis. HC 
was diagnosed based on macroscopic hematuria or sustained 
microhematuria with clinical symptoms de novo at least 10 days 
after HSCT. Hematuria ssociated with generalized bleeding ten- 
dency or bacteriuria was excluded. Urine samples were subjected 
to PCR and/or culture to detect viral infections. Results: Nineteen 
patients developed HC a median of 51 days (range 11-380) after 
HSCT with a 2-year cmnulative incidence of 14.2%. Adenovirus 
(AdV) was detected in the urine samples of 10 HC patients, of 
whom 8 had AdV type 1 I. Five of their 6 available serum samples 
were also positive for AdV type 11. The 3-year survival after the 
onset of HC was only 27%. Male sex and the development of
acute GVHD were identified as significant risk factors for HC by 
univariate analyses and both were shown to be independently sig- 
nificant using proportional hazard modeling with relative risks of 
7.52 (05% CI; 1.00-56.4, P=0.050) and 4.37 (95% CI; 1.65-11.6, 
P=0.0031), respectively. Conclusion: AdV type 11 infection 
appeared to play a major role in late onset HC in Japanese popula- 
tion. In addition, we identified male sex as a significant risk factor 
for HC. These findings uggested that late onset HC after HSCT 
may be caused by the reactivation of latent infection, because the 
male predominance has been already known in children with 
AdV-induced acute HC and also, its incidence was reported to be 
higher alnongJapanese children. 
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